REG - Truetide PLC - Investment update - Paraytec

TruetideAnnouncement

14/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260114:nRSN7797Oa&default-theme=true

RNS Number : 7797O  Truetide PLC  14 January 2026

[THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET
ABUSE REGULATION NO. 596/2014 (AS INCORPORATED INTO UK LAW BY VIRTUE OF THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED BY VIRTUE OF THE MARKET ABUSE
(AMENDMENT) (EU EXIT) REGULATIONS 2019). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS
NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN]

 

14 January 2026

 

Truetide plc

("Truetide" the "Company" or the "Group")

 

Investment update - Paraytec

 

Truetide (AIM: TRUE) announces an update on one of its investee companies,
Paraytec Limited ("Paraytec"). Truetide has a 100% interest in Paraytec.

Paraytec has initiated a focused development program to establish a
high-throughput, real-time fluorescent assay for alpha-synuclein fibril
formation using the CX300 detection system.

Alpha-synuclein aggregation is widely regarded as the central pathological
process in Parkinson's disease and other neurodegenerative diseases. Despite
intensive industry efforts, no disease-modifying therapy has yet reached the
market, in part due to the absence of robust, rapid and cost-effective
screening tools capable of identifying molecules that prevent or reverse
pathological aggregation.

The planned work comprises:

·    production and purification of recombinant wild-type and selected
pathogenic mutant alpha-synuclein proteins;

·    optimisation of site-specific fluorescent labelling compatible with
real-time measurement on the CX300 instrument;

·    full validation of the assay across multiple alpha-synuclein
variants; and

·    preparation of a technical methods paper and presentation at leading
international synucleinopathy conferences in 2026, supported by collaboration
with Professor Oliver Bandmann (Sheffield Institute for Translational
Neuroscience (SiTRAN)).

In the event of a successful completion, Paraytec expects to possess a
proprietary, accurate, rapid and low-cost assay that is currently unavailable
from any commercial source in a format optimised for the CX300 platform. The
directors of Paraytec believe that this assay has the potential to become a
preferred screening tool for pharmaceutical and biotechnology companies active
in the synucleinopathy field.

The combination of high sensitivity, real-time kinetics, and low sample
consumption positions the CX300 system to capture meaningful market share in
what is a multi-billion-dollar drug discovery segment. Initial
commercialisation routes under active consideration include reagent kit sales,
fee-for-service screening and strategic partnerships with instrument vendors
and therapeutic developers.

The Board of Truetide views this investment by Paraytec as a high-return
opportunity to establish clear technical differentiation for the CX300
platform in one of the most commercially attractive areas of neurodegenerative
disease research.

A further announcement will be made upon completion of the program and
publication of the validation data.

Trevor Brown, CEO of Truetide, commented:

"Paraytec remains close to making the scientific and commercial breakthrough
via its CX300 technology, that the directors of Truetide hope for. Although
somewhat protracted, the development work for a rapid Gram test continues,
this new program to establish a high-throughput, real-time fluorescent assay
for alpha-synuclein fibril formation significantly increases Paraytec's
exposure to the possibility of eventual commercialisation of the CX300."

 

 

 Truetide plc                                                   Tel: 01738 587555
 Trevor Brown, Chief Executive Officer

 Viv Hallam, Executive Director

 Allenby Capital Limited (Nominated Adviser and Joint Broker)   Tel: 020 3328 5656
 James Reeve / Ashur Joseph

 AlbR Capital Limited (Joint Broker)                            Tel: 020 7469 0936
 Duncan Vasey / Lucy Williams

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUBJMBTMTIBTRF



            Copyright 2019 Regulatory News Service, all rights reserved